2 days Ago By ABMN Staff
Syndax Pharmaceuticals ( NASDAQ:SNDX – Get Free Report ) had its target price boosted by stock analysts at Citigroup from $37.00 to $45.00 in a research report issued on Tuesday, Benzinga reports.
The brokerage presently has a “buy” rating on the stock. Citigroup’s price target suggests a potential upside of 182.13% from the company’s previous close.
Several other equities analysts have also recently issued reports on SNDX. StockNews.com upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 15th.
Stifel Nicolaus raised their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research note on Monday, October 14th.
The Goldman Sachs Group boosted their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th.
Barclays upped their price target on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research report on Thursday, August 15th.
Finally, UBS Group initiated coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 price objective for the company.
Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $37.
18. View Our Latest Research Report on SNDX Syndax Pharmaceuticals Stock Up 1.1 % Syndax Pharmaceuticals ( NASDAQ:SNDX – Get Free Report ) last posted its earnings results on Tuesday, November 5th.
The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.
15. The business had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.
16 million. During the same quarter last year, the firm earned ($0.73) earnings per share.
Equities research analysts anticipate that Syndax Pharmaceuticals will post -3.61 EPS for the current year. Institutional Investors Weigh In On Syndax Pharmaceuticals A number of hedge funds have recently bought and sold shares of the business.
Northwestern Mutual Wealth Management Co. bought a new stake in shares of Syndax Pharmaceuticals during the second quarter worth $27,000. Values First Advisors Inc.
purchased a new stake in shares of Syndax Pharmaceuticals in the third quarter worth about $30,000. nVerses Capital LLC bought a new stake in Syndax Pharmaceuticals in the second quarter valued at $33,000. Quantbot Technologies LP bought a new position in Syndax Pharmaceuticals in the 3rd quarter worth about $49,000.
Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Syndax Pharmaceuticals by 21.
3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd.
now owns 3,078 shares of the company’s stock worth $58,000 after acquiring an additional 541 shares in the last quarter. About Syndax Pharmaceuticals ( Get Free Report ) Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Read More Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
